Paper Details

  1. Home
  2. Paper Details

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with <i>FLT3</i> mutations.

Author: AdachiYoshiya, AkashiAkimi, ChenFangli, DateTomomi, FujikawaNorie, HagiwaraShinji, HayakawaFumihiko, HiraiAtsushi, IshikawaYuichi, KiyoiHitoshi, KurokawaNaoya, NakataniToshiyuki, NaoeTomoki, OguraHayato, SaitoKoichi, ShinWigyon, TakasakiMasaru, TeradaDaisuke, UdaKen, YamauraTakeshi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

FLT3 mutations are associated with poor prognosis in acute myeloid leukemia (AML). This study developed a novel FLT3 inhibitor, FF-10101, designed to possess selective and irreversible FLT3 inhibition. FF-10101 showed potent growth inhibitory effects on AML cell lines harboring FLT3 mutations, including those resistant to quizartinib.
Paper Details　
Original Abstract of the Article :
An activating mutation of <i>Fms-like tyrosine kinase 3</i> (<i>FLT3</i>) is the most frequent genetic alteration associated with poor prognosis in acute myeloid leukemia (AML). Although many FLT3 inhibitors have been clinically developed, no first-generation inhibitors have demonstrated clinical ef...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2017-05-786657

データ提供：米国国立医学図書館（NLM）

A Novel FLT3 Inhibitor: Hope for AML Patients

Acute myeloid leukemia (AML), a formidable foe, is like a relentless sandstorm sweeping across the landscape of the human body. This study introduces a novel FLT3 inhibitor, FF-10101, designed to combat this aggressive form of cancer. The authors investigated the efficacy of FF-10101 against AML cells with FLT3 mutations, a journey into the very heart of the cancer's genetic makeup.

FF-10101: A Potential Oasis in the Desert of AML

The study's findings, like a refreshing oasis in the desert of AML, offer hope for patients. FF-10101 demonstrated potent growth inhibitory effects on AML cell lines harboring FLT3 mutations, effectively halting the cancer's advance. This novel inhibitor exhibited excellent efficacy against a range of FLT3 mutations, including those resistant to existing inhibitors, a breakthrough akin to discovering a hidden water source amidst a seemingly barren desert.

A Beacon of Hope for AML Patients

This research provides a crucial step forward in the fight against AML. FF-10101, with its ability to overcome drug resistance, represents a beacon of hope for patients facing this challenging disease. This discovery, like a celestial guide leading a weary traveler through the night, offers a ray of optimism in the battle against AML.

Dr. Camel's Conclusion

This study offers hope for patients with acute myeloid leukemia (AML) by introducing a novel FLT3 inhibitor, FF-10101, which exhibits potent efficacy against FLT3 mutations, including those resistant to existing treatments. This research is like a desert explorer discovering a new oasis, providing a promising path towards a more effective treatment for AML.
Date :
  1. Date Completed 2019-05-13
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

29187377

DOI: Digital Object Identifier

10.1182/blood-2017-05-786657

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.